These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7011723)

  • 1. The plasma glucose response of normal fasting subjects to neutral regular and NPH biosynthetic human and purified pork insulins.
    Galloway JA; Spradlin CT; Root MA; Fineberg SE
    Diabetes Care; 1981; 4(2):183-8. PubMed ID: 7011723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosynthetic human insulin: effect in healthy men on plasma glucose and non-esterified fatty acids in comparison with highly purified pork insulin.
    Viberti GC; Pickup JC; Keen H; Bilous RW; Mattock M; Jarrett RJ; Glynne A; Rogers R
    Diabetes Care; 1981; 4(2):175-9. PubMed ID: 7011721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of porcine and human isophane (NPH) insulins in normal subjects.
    Owens DR; Jones IR; Birtwell AJ; Burge CT; Luzio S; Davies CJ; Heyburn P; Heding LG
    Diabetologia; 1984 Apr; 26(4):261-5. PubMed ID: 6376233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics and metabolic activity of biosynthetic NPH insulin evaluated by the glucose clamp technique.
    Massi Benedetti M; Bueti A; Mannino D; Bellomo G; Antonella MA; Calabrese G; Zega G; Brunetti P
    Diabetes Care; 1984; 7(2):132-6. PubMed ID: 6376009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects.
    Bantle JP; Neal L; Frankamp LM
    Diabetes Care; 1993 Dec; 16(12):1592-7. PubMed ID: 8299455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of biosynthetic human insulin and pork insulin in the Gerritzen test.
    Weinges K; Ehrhardt M; Enzmann F
    Diabetes Care; 1981; 4(2):180-2. PubMed ID: 7011722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of the activity of biosynthetic human insulin and pork insulin using the glucose clamp technique in normal subjects.
    Massi-Benedetti M; Burrin JM; Capaldo B; Alberti KG
    Diabetes Care; 1981; 4(2):163-7. PubMed ID: 7011718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human (recombinant DNA) and porcine NPH insulins are unequally effective in diabetic patients. A comparative study using continuous blood glucose monitoring.
    Richard JL; Rodier M; Cavalié G; Mirouze J; Monnier L
    Acta Diabetol Lat; 1984; 21(3):211-7. PubMed ID: 6393670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic and hormonal parameters after insulin-induced hypoglycemia in man, comparison between biosynthetic human insulin and purified pork insulin.
    Perez Fernandez R; Casanueva FF; Devesa J; Cabezas-Cerrato J
    Horm Metab Res; 1985 Jul; 17(7):351-4. PubMed ID: 2993143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosynthetic human insulin: pharmacokinetics and effects in healthy human volunteers.
    Brogard JM; Blickle JF; Pinget M; Stahl A; Dorner M
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):575-80. PubMed ID: 6360919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate-acting insulin preparations: NPH and lente.
    Deckert T
    Diabetes Care; 1980; 3(5):623-6. PubMed ID: 7192205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative potencies of human and pork insulin during i.v. and oral glucose tolerance test in lean and obese persons.
    Nesher R; Sinai J; Litvin Y; Cerasi E
    Isr J Med Sci; 1985 Nov; 21(11):905-11. PubMed ID: 3908398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of biosynthetic human insulin to erythrocytes of normal and insulin-dependent diabetic subjects: comparison with pork and human pancreatic insulin.
    Bachmann W; Sieger C; Lacher F; Lotz N
    Diabetes Care; 1981; 4(2):215-9. PubMed ID: 7011730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of human insulin (recombinant DNA)--regular, NPH, and mixtures--obtained by the Gerritzen method in healthy volunteers.
    Weinges K; Ehrhardt M; Nell G; Enzmann F
    Diabetes Care; 1982; 5 Suppl 2():67-70. PubMed ID: 6765545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin concentrations and time-action profiles of three different intermediate-acting insulin preparations in nondiabetic volunteers under glucose-controlled glucose infusion technique.
    Bottermann P; Gyaram H; Wahl K; Ermler R; Lebender A
    Diabetes Care; 1982; 5 Suppl 2():43-52. PubMed ID: 6765540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin.
    Olsson PO; Hans A; Henning VS
    Diabetes Care; 1987; 10(4):473-7. PubMed ID: 3304898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacologic studies with human insulin (recombinant DNA).
    Galloway JA; Root MA; Bergstrom R; Spradlin CT; Howey DC; Fineberg SE; Jackson RL
    Diabetes Care; 1982; 5 Suppl 2():13-22. PubMed ID: 6765524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic activity and pharmacokinetics of biosynthetic human insulin in the rat.
    Halban PA; Berger M; Gjinovci A; Renold AE
    Diabetes Care; 1981; 4(2):238-43. PubMed ID: 7011735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic and immunologic in vivo and in vitro studies with biosynthetic human insulin.
    Federlin K; Laube H; Velcovsky HG
    Diabetes Care; 1981; 4(2):170-4. PubMed ID: 7011720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Rosenstock J; Park G; Zimmerman J;
    Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.